ABOUT US

We have a broad portfolio (8 patent families) of issued and pending applications covering multiple indications/applications but for Alginate Encapsulated Insulin-Producing Cells Protected from Immune System Rejection.  Our cellular applications initially targeted to treatment of Diabetes Mellitus Type 1 through pancreatic islet cell transplantation and other indications include treatment of diabetic foot ulcers and peritoneal adhesions 

ABOUT OUR PLATFORM TECHNOLOGY

Our CXCL12 platform technology was exclusively licensed from Massachusetts General Hospital in 2013.  Our platform is broadly divided into cellular and non-cellular product lines and includes feasibility and long-term maintenance of transplanted human islet cells established in non human primate models

Cell Transplantation Program For Type 1 Diabetes

​

Funded by and developed in partnership with the JDRF

 

Diabetes Allotransplant Experiments
n Non-Human Primates  (NHP) are On-Going

 

Identifying the optimal β-stem cell partner for clinical studies

Non-Cellular Program Addresses Two Conditions

​

TREATMENT OF DIABETIC FOOT ULCERS

DFUs are a significant financial burden to health care systems and significantly
impact the Quality of Life indices for patients and their families

​

PREVENTION OF POST-PERITONEAL SURGERY ADHESIONS

An unmet medical need with more than 10 million  patients at risk
in the US and 25 million patients globally